Safety of Intravenous Immunoglobulin for Treatment of Auto-Immune Thrombocytopenia
- 1 January 1988
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 79 (2), 88-90
- https://doi.org/10.1159/000205727
Abstract
The incidence of hepatitis and HIV seroconversion has been examined in 64 patients receiving intravenous immunoglobulin (pepsin-treated at pH 4.0) for auto-immune thrombocytopenia. No evidence of HIV seroconversion has been detected. Five patients developed abnormal liver function following treatment. However, in no case could this be directly attributed to the treatment and no patient has developed chronic liver disease.This publication has 3 references indexed in Scilit:
- Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM‐induced antibody synthesis in vitroBritish Journal of Haematology, 1986
- High risk of non‐A non‐B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulinBritish Journal of Haematology, 1985
- NON-A, NON-B HEPATITIS OCCURRING IN AGAMMAGLOBULINAEMIC PATIENTS AFTER INTRAVENOUS IMMUNOGLOBULINThe Lancet, 1984